Abstract

PURPOSE OF REVIEW: The therapeutic armamentarium of adult soft-tissue sarcomas (STS) has widened in recent years. This was also due to increased consideration of their variegated histology. Trabectedin is a new chemotherapeutic agent, which significantly strengthens the armamentarium along this direction. RECENT FINDINGS: Trabectedin has proven efficacy in STS, mainly in leiomyosarcomas, liposarcomas, and other translocation-related sarcomas. Among further subgroups, its activity in uterine leiomyosarcomas is noteworthy. Moreover, it exerts special antitumor activity in myxoid liposarcomas, with distinct patterns of tumor response. Also, its mechanism of action is distinct in myxoid liposarcoma, apparently overcoming lipogenic cell differentiation block due to the tumor chromosomal translocation. Apart from histology, DNA repair mechanisms have been investigated as a predictive factor, with retrospective evidence in support. Combination of trabectedin with doxorubicin has limitations due to additive toxicity. Trabectedin is well tolerated as a single agent. Occasional major myelosuppression is possible but proper patient selection (with a focus on liver tests) and possibly steroid premedication are of help. SUMMARY: Trabectedin is a new marine-derived drug with a definite role in the 'histology-driven' medical therapy of STS. There is room for further investigation, to fully elucidate its efficacy in all STS and optimize tolerability.

Original languageEnglish
Pages (from-to)342-346
Number of pages5
JournalCurrent Opinion in Oncology
Volume22
Issue number4
DOIs
Publication statusPublished - Jul 2010

Fingerprint

trabectedin
Sarcoma
Myxoid Liposarcoma
Histology
Leiomyosarcoma
Therapeutics
Liposarcoma
Genetic Translocation
Premedication
DNA Repair
Doxorubicin
Patient Selection
Cell Differentiation
Neoplasms
Steroids

Keywords

  • drug therapy
  • soft-tissue sarcoma
  • trabectedin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Trabectedin therapy for sarcomas. / Casali, Paolo G.; Sanfilippo, Roberta; D'Incalci, Maurizio.

In: Current Opinion in Oncology, Vol. 22, No. 4, 07.2010, p. 342-346.

Research output: Contribution to journalArticle

@article{6e208f826b354111a7723a325edcb9b4,
title = "Trabectedin therapy for sarcomas",
abstract = "PURPOSE OF REVIEW: The therapeutic armamentarium of adult soft-tissue sarcomas (STS) has widened in recent years. This was also due to increased consideration of their variegated histology. Trabectedin is a new chemotherapeutic agent, which significantly strengthens the armamentarium along this direction. RECENT FINDINGS: Trabectedin has proven efficacy in STS, mainly in leiomyosarcomas, liposarcomas, and other translocation-related sarcomas. Among further subgroups, its activity in uterine leiomyosarcomas is noteworthy. Moreover, it exerts special antitumor activity in myxoid liposarcomas, with distinct patterns of tumor response. Also, its mechanism of action is distinct in myxoid liposarcoma, apparently overcoming lipogenic cell differentiation block due to the tumor chromosomal translocation. Apart from histology, DNA repair mechanisms have been investigated as a predictive factor, with retrospective evidence in support. Combination of trabectedin with doxorubicin has limitations due to additive toxicity. Trabectedin is well tolerated as a single agent. Occasional major myelosuppression is possible but proper patient selection (with a focus on liver tests) and possibly steroid premedication are of help. SUMMARY: Trabectedin is a new marine-derived drug with a definite role in the 'histology-driven' medical therapy of STS. There is room for further investigation, to fully elucidate its efficacy in all STS and optimize tolerability.",
keywords = "drug therapy, soft-tissue sarcoma, trabectedin",
author = "Casali, {Paolo G.} and Roberta Sanfilippo and Maurizio D'Incalci",
year = "2010",
month = "7",
doi = "10.1097/CCO.0b013e32833aaac1",
language = "English",
volume = "22",
pages = "342--346",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Trabectedin therapy for sarcomas

AU - Casali, Paolo G.

AU - Sanfilippo, Roberta

AU - D'Incalci, Maurizio

PY - 2010/7

Y1 - 2010/7

N2 - PURPOSE OF REVIEW: The therapeutic armamentarium of adult soft-tissue sarcomas (STS) has widened in recent years. This was also due to increased consideration of their variegated histology. Trabectedin is a new chemotherapeutic agent, which significantly strengthens the armamentarium along this direction. RECENT FINDINGS: Trabectedin has proven efficacy in STS, mainly in leiomyosarcomas, liposarcomas, and other translocation-related sarcomas. Among further subgroups, its activity in uterine leiomyosarcomas is noteworthy. Moreover, it exerts special antitumor activity in myxoid liposarcomas, with distinct patterns of tumor response. Also, its mechanism of action is distinct in myxoid liposarcoma, apparently overcoming lipogenic cell differentiation block due to the tumor chromosomal translocation. Apart from histology, DNA repair mechanisms have been investigated as a predictive factor, with retrospective evidence in support. Combination of trabectedin with doxorubicin has limitations due to additive toxicity. Trabectedin is well tolerated as a single agent. Occasional major myelosuppression is possible but proper patient selection (with a focus on liver tests) and possibly steroid premedication are of help. SUMMARY: Trabectedin is a new marine-derived drug with a definite role in the 'histology-driven' medical therapy of STS. There is room for further investigation, to fully elucidate its efficacy in all STS and optimize tolerability.

AB - PURPOSE OF REVIEW: The therapeutic armamentarium of adult soft-tissue sarcomas (STS) has widened in recent years. This was also due to increased consideration of their variegated histology. Trabectedin is a new chemotherapeutic agent, which significantly strengthens the armamentarium along this direction. RECENT FINDINGS: Trabectedin has proven efficacy in STS, mainly in leiomyosarcomas, liposarcomas, and other translocation-related sarcomas. Among further subgroups, its activity in uterine leiomyosarcomas is noteworthy. Moreover, it exerts special antitumor activity in myxoid liposarcomas, with distinct patterns of tumor response. Also, its mechanism of action is distinct in myxoid liposarcoma, apparently overcoming lipogenic cell differentiation block due to the tumor chromosomal translocation. Apart from histology, DNA repair mechanisms have been investigated as a predictive factor, with retrospective evidence in support. Combination of trabectedin with doxorubicin has limitations due to additive toxicity. Trabectedin is well tolerated as a single agent. Occasional major myelosuppression is possible but proper patient selection (with a focus on liver tests) and possibly steroid premedication are of help. SUMMARY: Trabectedin is a new marine-derived drug with a definite role in the 'histology-driven' medical therapy of STS. There is room for further investigation, to fully elucidate its efficacy in all STS and optimize tolerability.

KW - drug therapy

KW - soft-tissue sarcoma

KW - trabectedin

UR - http://www.scopus.com/inward/record.url?scp=77953911518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953911518&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e32833aaac1

DO - 10.1097/CCO.0b013e32833aaac1

M3 - Article

C2 - 20489618

AN - SCOPUS:77953911518

VL - 22

SP - 342

EP - 346

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 4

ER -